×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
QURE – uniqure n.v. - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
QURE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/1
09:07 am
qure
uniQure (NASDAQ: QURE) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $38.00 price target on the stock.
Medium
Report
uniQure (NASDAQ: QURE) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $38.00 price target on the stock.
3/11
11:07 pm
qure
uniQure (NASDAQ: QURE) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
uniQure (NASDAQ: QURE) was upgraded by analysts at StockNews.com to a "sell" rating.
3/4
12:27 pm
qure
uniQure (NASDAQ: QURE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Medium
Report
uniQure (NASDAQ: QURE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
2/28
12:49 pm
qure
uniQure (NASDAQ: QURE) had its price target lowered by analysts at Wells Fargo & Company from $35.00 to $30.00. They now have an "equal weight" rating on the stock.
Medium
Report
uniQure (NASDAQ: QURE) had its price target lowered by analysts at Wells Fargo & Company from $35.00 to $30.00. They now have an "equal weight" rating on the stock.
2/27
07:05 am
qure
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
High
Report
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
2/7
09:12 am
qure
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
Medium
Report
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
2/6
12:35 am
qure
uniQure (NASDAQ: QURE) was upgraded by analysts at StockNews.com to a "sell" rating.
Low
Report
uniQure (NASDAQ: QURE) was upgraded by analysts at StockNews.com to a "sell" rating.
2/3
07:05 am
qure
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
High
Report
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/5
05:33 pm
qure
Form 4 uniQure N.V. For: Mar 03 Filed by: Kapusta Matthew C
Medium
Report
Form 4 uniQure N.V. For: Mar 03 Filed by: Kapusta Matthew C
3/5
05:29 pm
qure
Form 4 uniQure N.V. For: Mar 03 Filed by: Abi-Saab Walid
Medium
Report
Form 4 uniQure N.V. For: Mar 03 Filed by: Abi-Saab Walid
3/5
05:25 pm
qure
Form 4 uniQure N.V. For: Mar 03 Filed by: KLEMT CHRISTIAN
Medium
Report
Form 4 uniQure N.V. For: Mar 03 Filed by: KLEMT CHRISTIAN
3/5
05:21 pm
qure
Form 4 uniQure N.V. For: Mar 03 Filed by: Potts Jeannette
Medium
Report
Form 4 uniQure N.V. For: Mar 03 Filed by: Potts Jeannette
2/27
07:33 pm
qure
Form 4 uniQure N.V. For: Feb 25 Filed by: Kapusta Matthew C
Medium
Report
Form 4 uniQure N.V. For: Feb 25 Filed by: Kapusta Matthew C
2/27
07:30 pm
qure
Form 4 uniQure N.V. For: Feb 25 Filed by: KLEMT CHRISTIAN
Medium
Report
Form 4 uniQure N.V. For: Feb 25 Filed by: KLEMT CHRISTIAN
2/27
08:46 am
qure
Form 10-K uniQure N.V. For: Dec 31
Medium
Report
Form 10-K uniQure N.V. For: Dec 31
2/27
08:04 am
qure
Form 8-K uniQure N.V. For: Feb 27
Low
Report
Form 8-K uniQure N.V. For: Feb 27
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
Uniqure NV (NASDAQ: QURE) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.
11.2%
6/16 UniQure NV weighs options including sale -Bloomberg [Reuters] 11.2%
10/25 Form 4 uniQure N.V. For: Oct 23 Filed by: Kapusta Matthew C 7.0%
5/10 uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B 7.0%
6/11 Uniqure NV (NASDAQ: QURE) had its "buy" rating re-affirmed by analysts at Janney Montgomery Scott. 5.9%
3/24 Uniqure NV (NASDAQ: QURE) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.2%
1/31 Form 4 uniQure N.V. For: Jan 31 Filed by: van Deventer Sander 5.1%
5/16 Uniqure NV (NASDAQ: QURE) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.3%
5/21 Uniqure NV (NASDAQ: QURE) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 3.9%
4/24 Form 4 uniQure N.V. For: Apr 22 Filed by: Kapusta Matthew C 3.8%
6/16 UniQure NV weighs options including sale -Bloomberg [Reuters] 11.2%
10/25 Form 4 uniQure N.V. For: Oct 23 Filed by: Kapusta Matthew C 7.0%
5/10 uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B 7.0%
6/11 Uniqure NV (NASDAQ: QURE) had its "buy" rating re-affirmed by analysts at Janney Montgomery Scott. 5.9%
3/24 Uniqure NV (NASDAQ: QURE) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.2%
1/31 Form 4 uniQure N.V. For: Jan 31 Filed by: van Deventer Sander 5.1%
5/16 Uniqure NV (NASDAQ: QURE) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 4.3%
5/21 Uniqure NV (NASDAQ: QURE) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 3.9%
4/24 Form 4 uniQure N.V. For: Apr 22 Filed by: Kapusta Matthew C 3.8%
TOP News Decliners
9/4
uniQure Announces Proposed Public Offering
-14.9%
5/12 Uniqure NV (NASDAQ: QURE) was given a new $81.00 price target on by analysts at Cantor Fitzgerald. They now have a "buy" rating on the stock. -7.0%
2/25 Uniqure NV (NASDAQ: QURE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.6%
7/29 Q2/2019 6/30/2019 EPS -0.830 ZacksConsensus N/A ActVsEst N/A - N/A -6.2%
9/5 uniQure Announces Pricing of its Public Offering -6.1%
3/6 Form 3/A uniQure N.V. For: Aug 07 Filed by: KLEMT CHRISTIAN -5.8%
1/29 Form 4 uniQure N.V. For: Jan 27 Filed by: Gut Robert -5.8%
3/2 Form 424B5 uniQure N.V. -5.6%
8/23 Form 4 uniQure N.V. For: Aug 21 Filed by: Kapusta Matthew C -5.0%
5/1 Uniqure NV (NASDAQ: QURE) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $71.00 price target on the stock. -4.9%
5/12 Uniqure NV (NASDAQ: QURE) was given a new $81.00 price target on by analysts at Cantor Fitzgerald. They now have a "buy" rating on the stock. -7.0%
2/25 Uniqure NV (NASDAQ: QURE) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -6.6%
7/29 Q2/2019 6/30/2019 EPS -0.830 ZacksConsensus N/A ActVsEst N/A - N/A -6.2%
9/5 uniQure Announces Pricing of its Public Offering -6.1%
3/6 Form 3/A uniQure N.V. For: Aug 07 Filed by: KLEMT CHRISTIAN -5.8%
1/29 Form 4 uniQure N.V. For: Jan 27 Filed by: Gut Robert -5.8%
3/2 Form 424B5 uniQure N.V. -5.6%
8/23 Form 4 uniQure N.V. For: Aug 21 Filed by: Kapusta Matthew C -5.0%
5/1 Uniqure NV (NASDAQ: QURE) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $71.00 price target on the stock. -4.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: